A: , MOQ - 1
[2] Appetite Suppression Melanotan II may suppress appetite as a secondary effect, likely due to its interaction with melanocortin receptors that regulate hunger signals
Oral semaglutide is indicated for use as an add-on combination therapy (with other glucose-lowering agents, including insulin) or as a monotherapy (in patients who are intolerant to metformin) for type 2 diabetes when diet and exercise do not provide adequate glycemic control
Disqualifying conditions include Diabetes, Kidney Disease, Gallbladder Disease, Pancreatitis, Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Syndrome Type 2, Thyroid Nodule that has not been evaluated, Pregnant or Breastfeeding Medical studies report patients losing 15-20% of their body weight on average after one year
Joule 4 , 26462660 (2020)
This information should be interpreted with a qualified healthcare provider as one data point among medical history, baseline metabolic labs, and lifestyle factors